1. Home
  2. COLL vs BLND Comparison

COLL vs BLND Comparison

Compare COLL & BLND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COLL
  • BLND
  • Stock Information
  • Founded
  • COLL 2002
  • BLND 2012
  • Country
  • COLL United States
  • BLND United States
  • Employees
  • COLL N/A
  • BLND N/A
  • Industry
  • COLL Biotechnology: Pharmaceutical Preparations
  • BLND EDP Services
  • Sector
  • COLL Health Care
  • BLND Technology
  • Exchange
  • COLL Nasdaq
  • BLND Nasdaq
  • Market Cap
  • COLL 1.0B
  • BLND 959.7M
  • IPO Year
  • COLL 2015
  • BLND 2021
  • Fundamental
  • Price
  • COLL $29.13
  • BLND $3.78
  • Analyst Decision
  • COLL Strong Buy
  • BLND Buy
  • Analyst Count
  • COLL 5
  • BLND 8
  • Target Price
  • COLL $43.60
  • BLND $4.86
  • AVG Volume (30 Days)
  • COLL 294.2K
  • BLND 2.1M
  • Earning Date
  • COLL 02-27-2025
  • BLND 02-27-2025
  • Dividend Yield
  • COLL N/A
  • BLND N/A
  • EPS Growth
  • COLL 757.11
  • BLND N/A
  • EPS
  • COLL 2.16
  • BLND N/A
  • Revenue
  • COLL $599,245,000.00
  • BLND $156,715,000.00
  • Revenue This Year
  • COLL $13.25
  • BLND $5.35
  • Revenue Next Year
  • COLL $17.67
  • BLND $20.75
  • P/E Ratio
  • COLL $13.47
  • BLND N/A
  • Revenue Growth
  • COLL 9.62
  • BLND N/A
  • 52 Week Low
  • COLL $28.39
  • BLND $2.08
  • 52 Week High
  • COLL $42.29
  • BLND $5.53
  • Technical
  • Relative Strength Index (RSI)
  • COLL 37.61
  • BLND 43.82
  • Support Level
  • COLL $29.39
  • BLND $3.59
  • Resistance Level
  • COLL $30.39
  • BLND $4.08
  • Average True Range (ATR)
  • COLL 1.00
  • BLND 0.19
  • MACD
  • COLL -0.24
  • BLND 0.01
  • Stochastic Oscillator
  • COLL 11.04
  • BLND 29.37

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About BLND Blend Labs Inc.

Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segments are; Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience, and the Title segment enables customers to streamline the title, settlement, and closing process at scale for mortgages, home equity lines of credit, and home equity loans. The majority of the revenue for the company is generated from the Blend Platform segment.

Share on Social Networks: